Emanuele Ostuni, Ph.D.
Emanuele Ostuni, Ph.D.

Dr. Ostuni is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees all commercialization aspects of the division's portfolio in Europe, including Kymriah, the first FDA-approved CAR-T cell therapy.  Dr. Ostuni has been with Novartis since 2012 in various executive roles.  Previously he held positions with Nano Terra, McKinsey & Co., and Surface Logix. Dr. Ostuni was also the co-founder of Enumeral Biomedical and served on its board of directors through its public listing in 2014.  Dr. Ostuni earned a Ph.D. in Physical Chemistry from Harvard University and a bachelor's and master's degree in Chemistry from Georgetown University.